BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29140658)

  • 1. Killing U.S. Slowly: Curing the Epidemic Rise of Cancer Drug Prices.
    White EK
    Food Drug Law J; 2017; 72(1):189-224. PubMed ID: 29140658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
    Bendicksen L; Rome BN; Avorn J; Kesselheim AS
    Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
    Mailankody S; Prasad V
    JAMA; 2016 Jul; 316(3):271-2. PubMed ID: 27149663
    [No Abstract]   [Full Text] [Related]  

  • 6. Paying for On-Patent Pharmaceuticals: Limit Prices and the Emerging Role of a Pay for Outcomes Approach.
    Fuller RL; Goldfield N
    J Ambul Care Manage; 2016; 39(2):143-9. PubMed ID: 26945298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rx: higher prices.
    Kosterlitz J
    Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rising Cost of Anticancer Medications in the United States.
    Jackson K; Nahata MC
    Ann Pharmacother; 2017 Aug; 51(8):706-710. PubMed ID: 28707550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating Drug Prices while Increasing Innovation.
    Conti RM; Frank RG; Gruber J
    N Engl J Med; 2021 Nov; 385(21):1921-1923. PubMed ID: 34767322
    [No Abstract]   [Full Text] [Related]  

  • 10. Reducing Branded Prescription Drug Prices: A Review of Policy Options.
    Alexander GC; Ballreich J; Socal MP; Karmarkar T; Trujillo A; Greene J; Sharfstein J; Anderson G
    Pharmacotherapy; 2017 Nov; 37(11):1469-1478. PubMed ID: 28805961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.
    Kanavos P; Ferrario A; Vandoros S; Anderson GF
    Health Aff (Millwood); 2013 Apr; 32(4):753-61. PubMed ID: 23569056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disclosing Prescription-Drug Prices in Advertisements - Legal and Public Health Issues.
    Dusetzina SB; Mello MM
    N Engl J Med; 2018 Dec; 379(24):2290-2293. PubMed ID: 30428275
    [No Abstract]   [Full Text] [Related]  

  • 13. Should the United States government regulate prescription prices? A critical review.
    Patterson JA; Carroll NV
    Res Social Adm Pharm; 2020 May; 16(5):717-723. PubMed ID: 31248779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebates-The Little-Known Factor Behind Increasing Drug List Prices.
    Rubin R
    JAMA; 2020 Mar; 323(9):812-813. PubMed ID: 32125400
    [No Abstract]   [Full Text] [Related]  

  • 16. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
    Academy of Managed Care Pharmacy
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How insurers' bargaining power affects drug prices in Medicare Part D.
    Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
    [No Abstract]   [Full Text] [Related]  

  • 18. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

  • 19. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.
    Gronde TV; Uyl-de Groot CA; Pieters T
    PLoS One; 2017; 12(8):e0182613. PubMed ID: 28813502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: Medicare Part D.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403844
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.